NEW YORK (GenomeWeb News) – GE Healthcare has acquired privately held MicroCal, a maker of microcalorimeter instruments used for studying molecular interactions in pharmaceutical, biomedical, and life science research, for an undisclosed sum, the firm said today.
MicroCal’s instruments provide detailed information on the structure, function, and binding properties of arrange of biomolecules including proteins, lipids, nucleic acids, and antibodies. According to GE Healthcare, MicroCal’s instruments are already used in over a thousand labs around the world.
The UK-based division of GE said that MicroCal’s products will complement its Biacore platform. GE Healthcare bought Biacore International for $390 million in 2006, providing the company with its first platform for protein interaction research.
GE Healthcare said that it would develop MicroCal’s facility in Northampton, Mass., into a center of excellence for microcalorimetry.
“The resources of GE Healthcare and the wider GE group will allow us to significantly widen our reach and to jointly develop new technologies, products and applications which will help scientists increase their understanding of molecular interactions,” MicroCal CEO Richard Brown said in a statement.
MicroCal was majority owned by private equity firm Riverside Partners, which had invested in the firm in 1999.